Business
Xeris Biopharma to Present at 41st Annual J.P. Morgan Healthcare Conference
CHICAGO--(BUSINESS WIRE)-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives
About this update from Xeris Biopharma Holdings, Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nXeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 12:00 pm Pacific Time. To access the presentation, please visit “Events” on the investor relations page of the Company’s website at www.xerispharma.com.\n\nAbout Xeris\n\nXeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.\n\nXeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn, or Instagram.\n\nForward-Looking Statements\n\nAny statements in this press release about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc. including statements regarding the timing or likelihood of expansion into additional markets, the likelihood of extending currently marketed products into new indications and uses, the potential utility of its formulation technology platforms and other statements containing the words “will,” “would,” “continue,” “expect,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environme...